Human Cys-loop receptors are important therapeutic targets. High-resolution structures are essential for rational drug design, but only a few are available due to difficulties in obtaining sufficient quantities of protein suitable for structural studies. Although expression of proteins in E. coli offers advantages of high yield, low cost, and fast turnover, this approach has not been thoroughly explored for full-length human Cys-loop receptors because of the conventional wisdom that E. coli lacks the specific chaperones and post-translational modifications potentially required for expression of human Cys-loop receptors. Here we report the successful production of full-length wild type human ␣7nAChR from E. coli. Chemically induced chaperones promote high expression levels of well-folded proteins. The choice of detergents, lipids, and ligands during purification determines the final protein quality. The purified ␣7nAChR not only forms pentamers as imaged by negativestain electron microscopy, but also retains pharmacological characteristics of native ␣7nAChR, including binding to bungarotoxin and positive allosteric modulators specific to ␣7nAChR. Moreover, the purified ␣7nAChR injected into Xenopus oocytes can be activated by acetylcholine, choline, and nicotine, inhibited by the channel blockers QX-222 and phencyclidine, and potentiated by the ␣7nAChR specific modulators PNU-120596 and TQS. The successful generation of functional human ␣7nAChR from E. coli opens a new avenue for producing mammalian Cys-loop receptors to facilitate structure-based rational drug design. . 2 The abbreviations used are: nAChR, nicotinic acetylcholine receptor; pLGIC, pentameric ligand-gated ion channel; ECD, extracellular domain; TMD, transmembrane domain; EM, electron microscopy.
Human Cys-loop receptors are promising therapeutic targets for various neurological disorders and diseases (1) (2) (3) (4) . Structure-based drug design for these receptors requires their high-resolution structures (5) . Although Cys-loop receptors contain only four major receptor types, including nicotinic acetylcholine receptors (nAChRs), 2 serotonin 5-HT3 receptors, glycine receptors, and GABA A receptors, each receptor type often has multiple subtypes that form numerous functional distinct receptors. Among the human Cys-loop receptors, highresolution structures have been obtained for only the ␤3 GABA A and ␣3 glycine receptors (6, 7) . Structures for other eukaryotic Cys-loop receptors include the mouse serotonin 5-HT3A receptor (8) , the zebrafish ␣1 glycine receptor (9) , the Caenorhabditis elegans GluCl (10, 11) and the muscle-type nicotinic acetylcholine receptor (nAChR) from Torpedo marmorota (12) . The dichotomy between the small number of available structures and the relatively large receptor population in the superfamily indicates the technical difficulties for structural determination of these receptors. One of the greatest challenges for structural determination of Cys-loop receptors and similarly complex human membrane proteins is the production of a large quantity of well-folded functional proteins.
The ␣7 nAChR (␣7nAChR) is one of the most abundant nAChR subtypes found in the brain (13, 14) . It is also expressed in a wide variety of non-neuronal tissues (15) . It has been implicated in diverse biological functions and is an important target for therapeutics (1) . ␣7nAChR mostly forms a homo-pentameric ligand-gated ion channel (pLGIC) that conducts calcium and other cations, though heteromeric ␣7␤2-nAChR has also been found in both heterologous expression systems and native neurons (16, 17) . Structures of the extracellular domain (ECD) and transmembrane domain (TMD) of ␣7nAChR have been determined separately by x-ray crystallography (18) and NMR (19) , but the full-length human ␣7nAChR has not previously been obtained from any species in a form suitable for structure determination (20, 21) .
Currently available structures for Cys-loop receptors were obtained from proteins expressed in mammalian (6, 8) and insect (7, 9 -11, 22) cell lines. We chose an alternate approach: to produce functional full-length human ␣7nAChR in E. coli. Production of recombinant proteins in E. coli is fast and inexpensive relative to other expression systems. In addition, E. coli may produce a more homogeneous population of purified proteins due to its limited ability for post-translational modifications (23) . In contrast, the native pathway for ␣7nAChR expression in mammalian cells involves subcellular trafficking through multiple subcellular compartments, where specific chaperone proteins and post-translational modifications aid folding and assembly. Thus, ␣7nAChR purified from mammalian or insect cells contain a mixture of receptors with different post-translational modifications representing various stages of maturation, including glycosylation, palmitoylation, and alternate disulfide conformations (24 -26) . These modifications were reported to be essential for the proper assembly and navigation of functional ␣7nAChR to the mammalian cell surface (24) . We hypothesize that these modifications are not needed for the proper folding and pentameric assembly of ␣7nAChR in the simpler expression environment of E. coli.
Here we report that ␣7nAChR purified from E. coli retains signature properties of native ␣7nAChR, including the ability to assemble into pentameric structures, to bind specific ligands, and to form functional ion channels that can be activated by agonists, inhibited by channel blockers, and enhanced by ␣7nAChR-specific positive allosteric modulators. The study demonstrates that E. coli is capable of producing human Cysloop receptors. It also suggests that the post-translational machinery may not be as essential as previously thought for expressing functional complex membrane proteins.
Results
Essential Conditions to Obtain Full-length Human ␣7nAChR from E. coli-Our expression construct consists of DNA encoding the wild-type full-length human ␣7nAChR with the signal sequence replaced by that of pelB (a bacterial leader sequence) for expression in E. coli. An 8-histidine tag was added to the C terminus to aid in purification. All subsequent mention of ␣7nAChR refers to this construct. Initial attempts to express full-length human ␣7nAChR in E. coli resulted in low expression levels and the formation of inclusion bodies. These problems could not be solved by expression of ␣7nAChR as a fusion protein with MBP, as a chimera with the bacterial homolog ELIC (27) or with various modifications to the protein sequence including codon optimization, deletion of the intracellular loop between the TM3 and TM4 helices, truncation of the N and C termini, and specific mutagenesis of suspected problem sequences. 3 The most significant improvement in the expression of ␣7nAChR was achieved by using osmotic shock (0.5 M sorbitol) at low temperature (15°C) to induce E. coli native chaperones (28) and using the ␣7nAChR agonist choline as a chemical chaperone (29) during induction ( Fig. 1a ). After testing multiple E. coli strains, we found Rosetta(DE3)pLysS to be most suitable for ␣7nAChR expression. For the choice of detergents, we found that n-dodecylphosphocholine (DPC) was most effective for extracting ␣7nAChR from cell membranes. Both DPC and n-dodecyl ␤-D-maltoside (DDM) were suitable for purification. Fig. 1b shows the size exclusion chromatography (SEC) profile of purified ␣7nAChR, which is consistent with a pentameric assembly. Under these conditions, we can obtain 1.2 Ϯ 0.2 mg pentameric ␣7nAChR from each liter induction culture (n ϭ 6). Purified ␣7nAChR migrates on SDS-PAGE with an apparent molecular weight near 50 kDa ( Fig. 1c) , consistent with the de-glycosylated monomer of ␣7nAChR (30). The protein identity was further confirmed by mass spectrometry, which showed more than 51% coverage of tryptic fragments ( Fig. 1d ). Although the C terminus was not identified by mass spectrometry, the full-length ␣7nAChR was ensured by C-terminal His-tag purification. Representative mass spectra are shown in the supplemental data.
Pentameric Assembly of Purified ␣7nAChR Visualized by EM-We used electron microscopy (EM) to analyze the oligomeric state of ␣7nAChR. To improve the quality of negativestain EM images, we reduced excess detergent by exchanging DDM to the chemically similar lauryl maltose neopentyl glycol (LMNG), which forms micelles at very low concentrations (0.01 mM). In the negative-stain EM images, ␣7nAChR was observed as discrete particles ( Fig. 2a ). From 113 micrographs, 7300 particles were sorted into 30 classes by two-dimensional classification ( Fig. 2b ). Among them, at least 13 classes represent essentially different versions of pentameric particles of ϳ6-7 nm in diameter with a pore in the middle (Fig. 2b, white box) , accounting for 47% of the particles analyzed (Fig. 2c ). The remaining classes may include various tilted views or aberrant particles. Under these sample conditions, ␣7nAChR appears to prefer an orientation showing the end-on view (i.e. top or bottom), precluding three-dimensional reconstruction.
Purified ␣7nAChR Retains Binding Sites for Bungarotoxin, PNU-120596, and TQS-Native human ␣7nAChR demonstrates nanomolar binding affinity for the antagonist bungarotoxin (31) , and micromolar binding affinity for positive allosteric modulators specific to ␣7nAChR, such as 1-
We measured binding of bungarotoxin to the purified ␣7nAChR immobilized on NiNTA plates using a chemiluminescent assay and found an affinity of 4 Ϯ 1 nM ( Fig. 3a) , which is similar to the reported value of ϳ5 nM measured from ␣7nAChR heterologously expressed in SH-EP1 human epithelial cells (31) . Using surface plasmon resonance, we also measured binding affinities of PNU-120596 and TQS to purified ␣7nAChR immobilized on a NiNTA chip ( Fig. 3, b and c) . For our purified ␣7nAChR, PNU-120596 had an apparent disassociation constant (K d ) of 1.1 Ϯ 0.1 M, which is close to the previously reported half maximal effective concentration (EC 50 ) of 1.6 Ϯ 0.4 M (32). TQS has a relatively lower affinity than PNU-120596 with a K d of 7.8 Ϯ 3.2 M, which is similar to the EC 50 of 6.2 Ϯ 0.6 M reported previously (33) . The results provide convincing evidence that human ␣7nAChR purified from E. coli retains binding sites for these ligands as observed in native membranes.
Purified ␣7nAChR Remains Functional-We measured the functional integrity of purified ␣7nAChR using quantitative bungarotoxin pull-down experiments and electrophysiology measurements in Xenopus oocytes.
␣-Bungarotoxin binding to ␣7nAChR has been used as a measure of functional ␣7nAChR at the cell surface (34) . We found that 92.9 Ϯ 0.3% of purified ␣7nAChR was pulled-down by ␣-bungarotoxin immobilized to Sepharose resin, as measured by absorbance at A 280 (n ϭ 3). The result suggests that most of the purified ␣7nAChR is folded properly in an active state.
Oocytes injected with purified ␣7nAChR showed activation currents upon applying the agonist choline, acetylcholine, or nicotine in TEVC experiments (Fig. 4a ). Note that choline is a selective agonist for ␣7nAChR (35) . The observed currents from protein injection (6 Ϯ 2 nA, n ϭ 5) are smaller than currents from cRNA injection (150 Ϯ 50 nA, n ϭ 5). The smaller current is typical for purified channel proteins injected into oocytes (36 -38) . Oocytes tolerate injection of only a limited amount of reconstituted protein. We injected only 5 ng of purified ␣7nAChR compared with 25 ng of cRNA. Each cRNA molecule can result in hundreds of synthesized protein molecules (39) . Therefore, it is anticipated that cRNA injection will gen- erate many more channels and larger currents than protein injection. The currents were absent from oocytes injected with buffer only (Fig. 4a) . Fast activation and desensitization are signature properties of ␣7nAChR (13) . An expanded time scale demonstrates similar kinetics for currents resulting from protein and cRNA injections (Fig. 4b ). Representative traces in Fig.  4c show that the currents were inhibited by channel blockers N-(2,6-dimethyl-phenylcarbamoylmethyl) trimethylammonium chloride (QX-222) (40) (79 Ϯ 3% versus 74 Ϯ 5% for protein and cRNA injections, respectively, n ϭ 5) and phencyclidine (PCP) (41, 42) (92 Ϯ 2% versus 93 Ϯ 3% for protein and cRNA injections, respectively, n ϭ 5). Protein-and cRNA-injected oocytes also showed similar potentiation by PNU-120596 (9 Ϯ 3 versus 12 Ϯ 3 for protein and cRNA injections, respectively, n ϭ 5) and TQS (18 Ϯ 5 versus 23 Ϯ 4 for protein and cRNA injections, respectively, n ϭ 5), both of which are ␣7nAChR specific positive allosteric modulators (32, 43) . Representative traces are shown in Fig. 4d . These results demonstrate that human ␣7nAChR generated from E. coli can form functional channels that retain pharmacological characteristics of native ␣7nAChR.
Discussion
Among all the members of the Cys-loop superfamily of ligand gated ion channels, ␣7nAChR is known to be particularly difficult to express (20, 21) . Its functional expression in mammalian cells is cell-type dependent, which has been linked to the requirement for specific chaperone proteins and post-translational modifications (24) . Even in permissive cells, it has been estimated that only 62% of the total ␣7nAChR protein present in the cell is in a mature functional form (31) . This may be a problem inherent to heterologous expression in eukaryotic cells, not only for ␣7nAChR but also for other homologous receptors. Indeed, those eukaryotic Cys-loop channels for which structures have been successfully determined have all been mutagenized or processed in vitro in an effort to improve monodispersity of the final product (6 -11, 22) . Production of functional human ␣7nAChR in E. coli suggests that specific chaperone proteins and post-translational modifications are not required for channel function, but instead are a consequence of sub-cellular trafficking in eukaryotic cells. Posttranslational modification in E. coli is limited (23) , which may improve homogeneity of the protein expression. Our results show that the E. coli chaperones induced by osmotic and cold shock as well as the chemical chaperone choline are sufficient for producing large quantities of well-folded ␣7nAChR.
In addition to the expression conditions, the oligomeric state of ␣7nAChR was sensitive to purification procedures. Under optimal conditions, the pentameric form was stable for 2 or 3 days at 4°C. However, the isolated pentamer fraction had a tendency to aggregate under conditions of low ionic strength or detergent concentration; or to dissociate to smaller oligomeric structures under conditions of high ionic strength or detergent concentration. The tendency to form multiple oligomeric structures may be an intrinsic property of ␣7nAChR. Metabolically labeled ␣7nAChR obtained from mammalian PC12 cell culture through microscale purification was found to form multiple oligomeric structures (44) . A mutated construct of the zebra finch ␣7nAChR expressed in HEK293F cells also showed micro-aggregation by negative-stain EM (45) . Our study suggests that homogenous ␣7nAChR can be obtained by carefully controlling the purification conditions and time window.
E. coli readily expresses the bacterial homologues of Cysloop receptors, such as GLIC (46, 47) and ELIC (48) . Because of the traditional wisdom that post-translational modification is essential for producing functional eukaryotic channel proteins, using E. coli to express mammalian Cys-loop receptors is almost uncharted territory. Our results challenge that traditional wisdom and suggest that careful manipulation of expression conditions can allow production of functional human ␣7nAChR in E. coli. It is likely that other members of the Cysloop receptor superfamily can also be produced from E. coli Functional Human ␣7nAChR from E. coli AUGUST 26, 2016 • VOLUME 291 • NUMBER 35
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following similar protocols. Given the pharmaceutical interest in these receptors as therapeutic targets, perhaps their expression in E. coli should be revisited.
Experimental Procedures
Expression and Purification of Human ␣7nAChR from E. coli-Human ␣7nAChR (UniProtKB P36544: ACHA7_ HUMAN) with the pelB leader sequence (removed during expression) and a C-terminal 8-histidine tag was expressed from the T7 promoter using the expression vector pTBSG1 (49) . There was no modification to the native ␣7nAChR sequence. The protein was expressed in Rosetta 2(DE3)pLysS (Novagen) using the Marley protocol (50). Induction with 0.2 mM IPTG was for 16 h at 15°C in LB broth containing 500 mM sorbitol and 10 mM choline. Cells from 1 liter induction medium were resuspended in 25 ml of buffer A containing 50 mM Tris, pH 8, 500 mM NaCl, 500 mM sucrose, 10 mM choline, 10% glycerol, and HALT protease inhibitor. All subsequent operations were at 4°C. Cells were lysed using an Avestin Emulsiflex-C3 homogenizer. The cell lysate was adjusted to 0.33% DPC and 20 mM imidazole and incubated for 2 h. The insoluble fraction was then removed by ultracentrifugation (1 h 200 k ϫ g) and the supernatant incubated with 3 ml of NiNTA resin (GEHealthcare) for 2 h, mixing by inversion. The resin was transferred to a column and washed with 10 column volumes (cv) of buffer A, followed by 10 cv buffer B containing 100 mM imidazole, 10% glycerol, 150 mM NaCl, and 0.05% DDM. ␣7nAChR was eluted with buffer C containing 250 mM imidazole, 10% glycerol, 150 mM NaCl, and 0.05% DDM. The purified protein was concentrated to 0.5 mg/ml using a Vivaspin 2 molecular weight cut-off 100,000 centrifugal filter (Sartorius, Germany), and the pentamer fraction was isolated by SEC using a S200 10/300 or S200 3.2/300 column (GEHealthcare). Protein purity and identity were assessed by SDS-PAGE and Western blotting analysis, respectively. Western blotting analysis was performed using a monoclonal mouse antibody to the C terminus of ␣7nAChR (catalogue number 60220 -1-Ig, Lot number 10001012, ProteinTech). Antibody specificity was confirmed by the manufacturer and by comparison of E. coli extracts with and without ␣7nAChR expression.
Proteomics Analysis to Confirm ␣7nAChR Identity-Purified ␣7nAChR was digested using an in-solution digestion protocol as described previously (51, 52) . Tryptic peptides of ␣7nAChR were injected into a 75 m ϫ 150 mm BEH C18 column (particle size 1.7 m, Waters), separated using a Waters nanoAC-QUITY Ultra Performance LC TM (UPLC TM ) System (Waters, Milford, MA) and subjected to LC-MS/MS analyses performed on a Thermo Scientific LTQ Orbitrap XL (Thermo Scientific) with a Finnigan Nanospray II electrospray ionization source in the data dependent mode using the TOP10 strategy (53) . In brief, each scan cycle was initiated with a full MS scan of high mass accuracy (400 -2,000 m/z; acquired in the Orbitrap Elite at 6 ϫ 104 resolution setting and automatic gain control (AGC) target of 106), followed by MS/MS scans (AGC target 5,000; threshold 3,000) in the linear ion trap on the 10 most abundant precursor ions. Selected ions were dynamically excluded for 30 s. Singly charged ions were excluded from MS/MS analysis. MS/MS spectra were searched by using the SEQUEST algo-rithm against a composite database containing the International Protein Index (IPI) (human) protein sequences and their reverse sequences. Search parameters allowed for two missed tryptic cleavages, a mass tolerance of Ϯ10 ppm for precursor ion, a mass tolerance of Ϯ0.02 Da for product ion, a static modification of 57.02146 Da (carboxyamidomethylation) on cysteine and a dynamic modification of 15.99491 Dalton (oxidation).
Negative Stain Electron Microscopy and Image Analysis-To prepare samples for electron microscopy, purified ␣7nAChR was subjected to SEC in 10 mM HEPES pH 7.4, 150 mM NaCl, and 0.002% LMNG. Samples (3 l) from the SEC peak fraction were absorbed to a glow-discharged 400-mesh carbon-coated copper grid. Samples were then stained with two drops of uranyl acetate (2%), blotted with filter paper, and imaged on a TF20 electron microscope (FEI, Hillsboro, OR) equipped with a field emission gun. Images were recorded at ϫ100,000 magnification on a 4k ϫ 4k Gatan Ultrascan CCD camera (Gatan, Warrendale, PA). From 113 micrographs, a total of 7300 particles were picked using EMAN2 (54) and then extracted and classified using Relion 1.4 (55) .
Binding Assays-A chemiluminescent assay was used to measure binding of biotinylated bungarotoxin to purified ␣7nAChR immobilized on 96-well NiNTA plates (Thermo-Fisher, Waltham, MA). Briefly, each well was incubated with 30 l 100 g/ml purified ␣7nAChR for 6 h at 4°C, then washed three times with 50 mM sodium phosphate buffer pH 7.4, 0.025% DDM, 0.05 mg/ml asolectin, followed by another wash with 50 mM sodium phosphate, pH 7.4, 0.1 mg/ml asolectin. Biotin conjugated bungarotoxin (ThermoFisher, Waltham, MA) was added at the indicated concentrations in 50 mM sodium phosphate buffer and incubated overnight at 4°C. Excess bungarotoxin was removed by three 200-l washes with Tris-buffered saline, 0.05% Tween. Avidin-HRP (Thermo-Fisher, Waltham, MA) was added to each well at 1 g/ml for 1 h and then developed using SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher, Waltham, MA). Negative controls were treated identically, except no ␣7nAChR was present. For the ␣7nAChR-specific positive allosteric modulators PNU-120596 and TQS, steady-state surface plasmon resonance responses to ligand binding to purified ␣7nAChR as a function of ligand concentration were measured at 25°C using a Biacore 3000 with the NTA sensor chip (GE Healthcare, Uppsala, Sweden). ␣7nAChR was immobilized to the NTA sensor chip with densities between 1000 and 2000 RU. Responses to ligand binding were measured in phosphate-buffered saline with 0.005% lauryldimethylamine-N-oxide and 1% dimethyl sulfoxide at a flow rate of 30 l/min. After reference and buffer subtraction, the steady state regions of each sensogram for PNU-120596 and TQS for a series of concentrations up to the solubility limits of the respective ligand were averaged and used to plot the SPR response (n ϭ 3). Dissociation constants were derived by non-linear regression analysis using a Langmuir isotherm equation.
␣-Bungarotoxin-Sepharose Pull-down Experiments-␣-Bungarotoxin Sepharose was prepared by reacting 1 mg of bungarotoxin with 200 l of cyanogen bromide-activated Sepharose (GE Healthcare), and then blocking unreacted sites following the manufacturer's recommendations. Control-Sepharose was prepared by blocking reactive sites in the absence of ␣-bungarotoxin. For each experiment, 3.2 nmol of purified ␣7nAChR was incubated overnight with 20 l each of the control-resin or ␣-bungarotoxin-resin. The amount of ␣7nAChR pulled down was measured by the absorbance at 280 nm and reported as the mean ratio of ␣-bungarotoxin resin/control resin based on three independent experiments.
Electrophysiology-Functional measurements of purified ␣7nAChR injected into Xenopus oocytes were performed using two electrode voltage clamp experiments (56) . We injected additional oocytes with either saline or cRNA encoding ␣7nAChR as negative and positive controls, respectively. For cRNA injections, 25 ng cRNA for ␣7nAChR was co-injected with 25 ng of cRNA for RIC3 to increase surface expression of ␣7nAChR. For protein injections, the purified pentameric ␣7nAChR was reconstituted into vesicles composed of egg phosphatidylcholine, phosphatidic acid, and cholesterol in a 3:1:1 molar ratio. Detergent was removed using Biobeads SM-2 (Bio-Rad) following the manufacturer's recommendations. 5 ng of reconstituted ␣7nAChR was injected into Xenopus oocytes. After 1-2 days, channel function was measured in a 20-l oocyte recording chamber (Automate Scientific) clamped at Ϫ60 mV with an OC-725C Amplifier (Warner Instruments). The recording solutions contained 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.0 and the indicated concentrations of the agonists acetylcholine, choline, nicotine, the channel blockers QX-222, and PCP, and the ␣7nAChR-specific positive allosteric modulators PNU-120596, and TQS. Data were collected and processed using Clampex 10 software (Molecular Devices).
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